Development of methods to analyse Plasmodium falciparum single nucleotide polymorphisms in PfCRT (А > C), PfMDR1 (A > T) and PfDHFR (G > A) genes that determine resistance to quinoline, diamino-pyrimidine and sulfonamide groups of antimalarial drugs

封面

如何引用文章

全文:

详细

BACKGROUND: The drug resistance of tropical malaria pathogens to mefloquine, chloroquine, pyrimethamine and their derivatives is associated with three single nucleotide polymorphisms: K76T (A403627C), S1034C (A960989T) and S108N (G748410A). These mutations are linked to changes in the structure of the PfCRT and PfMDR1 genes of Plasmodium falciparum.

AIM: Develop methods for identifying single nucleotide polymorphisms that are suitable for early diagnosis of drug-resistant forms of tropical malaria.

RESULTS: A method was developed based on restriction fragment length analysis using ApoI endonuclease to detect the K76T polymorphism (A403627C). The criterion for determining parasite resistance to chloroquine was the appearance of a single 145 bp band on the electropherogram. The genotype of the pathogens remained unchanged and their drug sensitivity was preserved, as indicated by the separation of two fragments of 98 and 47 bp.

A system for detecting S108N (G748410A) was developed using the Bse1I endonuclease. The appearance of a single 507 bp band on the electropherogram indicated the mutant genotype of the pathogens, while the appearance of two fragments (323 and 184 bp) indicated an unchanged genotype and preservation of drug sensitivity of plasmodiae.

To identify the A > T polymorphism in the PfMDR1 gene at position 960989, polymerase chain reaction technology will be used with two allele-specific primers. One primer will detect the wild-type allele, and the other will detect the mutant genotype. The amplifiable fragment of the PfMDR1 gene contains sequences of the 1034th codon. Depending on the P. falciparum genotype, 261 bp fragments will be obtained with one of the allele-specific primers.

CONCLUSION: Criteria for assessing drug resistance of P. falciparum were developed based on the analysis of obtained data. Haplotypes K76T (band 145 bp) and S1034C (band 262 bp with the direct primer S1034C-F2) serve as indicators of the relative resistance of pathogens to chloroquine, mefloquine, and their derivatives. Positive results of examination for haplotype S108N (bands 323 and 184 bp) should be considered as a sign of decreased sensitivity to pyrimethamine. The developed methods can be used in clinical practice and for epidemiological monitoring.

作者简介

Artem Ariukov

Military Medical Academy

编辑信件的主要联系方式.
Email: arukov.artem@yandex.ru
ORCID iD: 0000-0001-8774-5467

postgraduate student

俄罗斯联邦, Saint Petersburg

Aleksey Solovyov

Military Medical Academy

Email: solopiter@gmail.com
ORCID iD: 0000-0002-3731-1756

MD, Dr. Sci. (Medicine), Professor

俄罗斯联邦, Saint Petersburg

Vladimir Kapatsyna

S.P. Botkin Clinical infectious hospital

Email: ingashi@mail.ru
ORCID iD: 0000-0002-8959-0873

the Head of Department

俄罗斯联邦, Saint Petersburg

Anna Krutikova

Military Medical Academy

Email: anntim2575@mail.ru
ORCID iD: 0000-0003-2561-145X

MD, Cand. Sci. (Biology)

俄罗斯联邦, Saint Petersburg

Vladimir Romanenko

Military Medical Academy

Email: izvestiavmeda@mail.ru
俄罗斯联邦, Saint Petersburg

Aleksander Kovalenko

Military Medical Academy

Email: ank561@mail.ru
ORCID iD: 0000-0002-2976-8051

MD, Dr. Sci. (Medicine), Associate Professor

俄罗斯联邦, Saint Petersburg

Akim Kolesnik

Military Medical Academy

Email: izvestiavmeda@mail.ru
ORCID iD: 0009-0001-5809-9694
俄罗斯联邦, Saint Petersburg

Artem Zinin

Military Medical Academy

Email: izvestiavmeda@mail.ru
ORCID iD: 0009-0000-4308-7554
俄罗斯联邦, Saint Petersburg

参考

  1. Mulenga MC, Sitali L, Ciubotariu II, et al. Decreased prevalence of the Plasmodium falciparum PfCRT K76T and Pfmdr1 and N86Y mutations post-chloroquine treatment withdrawal in Katete District, Eastern Zambia. Malar J. 2021;20(1):329. doi: 10.1186/s12936-021-03859-z
  2. Hassen J, Alemayehu GS, Dinka H, Golassa L. High prevalence of PfCRT 76T and Pfmdr1 N86 genotypes in malaria infected patients attending health facilities in East Shewa zone, Oromia Regional State, Ethiopia. Malar J. 2022;21(1):286. doi: 10.1186/s12936-022-04304-5
  3. Njiro BJ, Mutagonda RF, Chamani AT, et al. Molecular surveillance of chloroquine-resistant Plasmodium falciparum in sub-Saharan African countries after withdrawal of chloroquine for treatment of uncomplicated malaria: A systematic review. J Infect Public Health. 2022;15(5):550–557. doi: 10.1016/j.jiph.2022.03.015
  4. Yobi DM, Kayiba NK, Mvumbi DM, et al. Assessment of Plasmodium falciparum anti-malarial drug resistance markers in pfk13-propeller, PfCRT and pfmdr1 genes in isolates from treatment failure patients in Democratic Republic of Congo, 2018–2019. Malar J. 2021;20(1):144. doi: 10.1186/s12936-021-03636-y
  5. Shrivastava SK, Gupta RK, Mahanta J, Dubey ML. Correlation of molecular markers, Pfmdr1-N86Y and PfCRT-K76T, with in vitro chloroquine resistant Plasmodium falciparum, isolated in the malaria endemic states of Assam and Arunachal Pradesh, Northeast India. PLoS One. 2014;9(8):e103848. doi: 10.1371/journal.pone.0103848
  6. Wang X, Zhang X, Chen H, et al. Molecular determinants of sulfadoxine-pyrimethamine resistance in Plasmodium falciparum isolates from Central Africa between 2016 and 2021: wide geographic spread of highly mutated Pfdhfr and Pfdhps alleles. Microbiol Spectr. 2022;10(5): e0200522. doi: 10.1128/spectrum.02005-22
  7. Amir A, Cheong FW, De Silva JR, Lau YL. Diagnostic tools in childhood malaria. Parasit Vectors. 2018;11(1):53. doi: 10.1186/s13071-018-2617-y
  8. Jiang T, Huang Y, Cheng W, et al. Multiple single-nucleotide polymorphism detection for antimalarial pyrimethamine resistance via allele-specific PCR coupled with gold nanoparticle-based lateral flow biosensor. Antimicrob Agents Chemother. 2021;65(3):e01063–20. doi: 10.1128/aac.01063-20
  9. Sharma D, Lather M, Dykes CL, et al. Disagreement in genotyping results of drug resistance alleles of the Plasmodium falciparum dihydrofolate reductase (Pfdhfr) gene by allele-specific PCR (ASPCR) assays and Sanger sequencing. Parasitol Res. 2016;115(1):323–328. doi: 10.1007/s00436-015-4750-2
  10. Jiang T, Cheng W, Yao Y, et al. Molecular surveillance of anti-malarial resistance Pfdhfr and Pfdhps polymorphisms in African and Southeast Asia Plasmodium falciparum imported parasites to Wuhan, China. Malar J. 2020;19(1):434. doi: 10.1186/s12936-020-03509-w
  11. Dalimi A, Mosawi SH, Fotouhi-Ardakani R, Dalirghafari A. Evaluation of Drug Resistant Genotypes to Fansidar and Chloroquine by Studying Mutation in Pfdhfr and Pfmdr1 Genes in Plasmodium falciparum Isolates from Laghman Province, Afghanistan. IIran J Parasitol. 2022;17(1):18–27. doi: 10.18502/ijpa.v17i1.9012
  12. Cheng W, Song X, Zhu H, et al. A rapid and specific genotyping platform for Plasmodium falciparum chloroquine resistance via allele-specific PCR with a lateral flow assay. Microbiol Spectr. 2022;10(2): e0271921. doi: 10.1128/spectrum.02719-21
  13. Sambrook J, Russell DW. Purification of nucleic acids by extraction with phenol: chloroform. Cold Spring Harbor Protocols. 2006;2006(1): pdb.prot4455. doi: 10.1101/pdb.prot4455
  14. Lakshmanan V, Bray PG, Verdier-Pinard D, et al. A critical role for PfCRT K76T in Plasmodium falciparum verapamil-reversible chloroquine resistance. EMBO J. 2005;24(13):2294–2305. doi: 10.1038/sj.emboj.7600681
  15. Anderson TJ, Nair S, Qin H, et al. Are transporter genes other than the chloroquine resistance locus (PfCRT) and multidrug resistance gene (pfmdr) associated with antimalarial drug resistance? Antimicrob Agents Chemother. 2005;49(6):2180–2188. doi: 10.1128/aac.49.6.2180–2188.2005
  16. Wernsdorfer WH, Noedl H. Molecular markers for drug resistance in malaria: use in treatment, diagnosis and epidemiology. Curr Opin Infect Dis. 2003;16(6):553–558. doi: 10.1097/01.qco.0000104295.87920.fd

补充文件

附件文件
动作
1. JATS XML

版权所有 © Eco-Vector, 2024

Creative Commons License
此作品已接受知识共享署名-非商业性使用-禁止演绎 4.0国际许可协议的许可。

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).